title: [Systemic sclerosis in a patient suffering from breast cancer].
abstract: Scleroderma is the general disease of the connective tissue, which can be characterized by the proliferation of the connective tissue and fibrosis. According to the results of international studies scleroderma is frequently accompanied by neoplastic diseases, among which the most often occurring is the neoplastic pathology of the breast and the lungs. In May 2007, in the case of our 40-year-old woman patient the histological examination of the tumor we noticed in the left breast verified invasive carcinoma. In December 2007, after neoadjuvant chemotherapy she had a left mastectomy and then she was given postoperative irradiation, hormone therapy and trastuzumab (Herceptin) treatment, which was suspended in December 2008 due to oedema and fibrosis all over the body. In May 2009 she first visited the immunology outpatient department of our clinic, where we started her examination because of our suspicion of scleroderma and her cutaneous fibrosis symptoms, which was established on the basis of the examinations (immunoserology, body plethysmography, diffusing capacity of the lung for carbon monoxide, capillary microscopy, barium swallow) and her symptoms. She was given a conservative therapy (pentoxyphylline, amlodipine, nitroglycerin). Scleroderma arising after the neoplastic process of the breast is usually much more progressive than the primary disease. International reports also show a close correlation between breast cancer and the development of scleroderma, but its exact mechanism is not yet clear.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, III. sz. Belgyógyászati Klinika, Klinikai Immunológiai Tanszék, Debrecen, Hungary. orsi0618@gmail.com
authors.forename: Orsolya
authors.initials: O
authors.lastname: Szabolcsi
authors.forename: Annamária
authors.initials: A
authors.lastname: Nagy-Toldi
authors.forename: Margit
authors.initials: M
authors.lastname: Zeher
authors.forename: Judit
authors.initials: J
authors.lastname: Végh
mesh_terms: D000328:Adult; D017311:Amlodipine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D004487:Edema / Q000209:etiology; D005260:Female; D005355:Fibrosis / Q000209:etiology; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology*; D020360:Neoadjuvant Therapy / Q000379:methods; D005996:Nitroglycerin / Q000008:administration & dosage; D010431:Pentoxifylline / Q000008:administration & dosage; D011859:Radiography; D018714:Radiotherapy, Adjuvant; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D012867:Skin / Q000473:pathology*; D014665:Vasodilator Agents / Q000008:administration & dosage
chemical_list: D014665:Vasodilator Agents; D017311:Amlodipine; D005996:Nitroglycerin; D010431:Pentoxifylline